Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724693 · ClinicalTrials.gov registry record · Phase 1
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
A Phase 1 study of Healthy Volunteer and Hepatic Impairment, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05724693 is a Phase 1 study of Healthy Volunteer and Hepatic Impairment that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 39 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05724693, a Phase 1 study of Healthy Volunteer and Hepatic Impairment, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
Conditions Studied
Interventions
- DRUG Bemnifosbuvir (BEM)
Study Locations (1)
Florida
- Atea Study Site Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2024-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05724693
The ClinicalTrials.gov registry entry for NCT05724693 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (81% lower). The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 1 intervention - of which Bemnifosbuvir (BEM) is the first listed.
NCT05724693 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05724693 about?
NCT05724693 is a clinical study titled "Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function". To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
What is the current status of trial NCT05724693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-01-30. Estimated completion is 2024-04-23.
What conditions does trial NCT05724693 study?
This clinical trial studies the following conditions: Healthy Volunteer, Hepatic Impairment.
What interventions are being tested in trial NCT05724693?
The interventions under investigation include: Bemnifosbuvir (BEM) (DRUG).
Who is sponsoring clinical trial NCT05724693?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05724693 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.